AstraZeneca PLC (LON:AZN - Get Free Report) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of £109.18 ($147.38) and traded as high as £121.26 ($163.69). AstraZeneca shares last traded at £119.63 ($161.49), with a volume of 1,000,986 shares.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on AZN shares. Berenberg Bank reaffirmed a "buy" rating and set a GBX 140 target price on shares of AstraZeneca in a research report on Friday, May 16th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a £110 price objective on shares of AstraZeneca in a research report on Wednesday, July 30th. Finally, Shore Capital reissued a "buy" rating and issued a £135 price target on shares of AstraZeneca in a research report on Tuesday, July 29th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 9,660.
Check Out Our Latest Research Report on AZN
AstraZeneca Trading Down 0.6%
The business's 50-day moving average price is £108.80 and its two-hundred day moving average price is £109.26. The company has a market capitalization of £227.23 billion, a P/E ratio of 32.37, a PEG ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.
Insiders Place Their Bets
In related news, insider Aradhana Sarin sold 9,563 shares of the company's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of £115.12, for a total value of £1,100,892.56. Insiders own 0.04% of the company's stock.
AstraZeneca Company Profile
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Further Reading
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
